what is the difference
GHK-Cu vs Matrixyl
Two lawful cosmetic ingredients, sold as rivals, with a shared chemical core sitting inside one of them.
GHK-Cu, sold in a cosmetic as copper tripeptide-1, is glycyl-histidyl-lysine holding a copper ion: three amino acids and a metal that occur together in human blood plasma. Matrixyl is the trade name for palmitoyl pentapeptide-4, written pal-KTTKS: five amino acids from type I collagen with palmitic acid attached at the front to help the fragment cross skin.
Both are listed cosmetic ingredients, lawfully sold and advertised on how skin looks [8] [9], and marketed as competing routes to the same appearance goal. The more useful fact sits underneath the branding: one of the peptides inside the Matrixyl 3000 blend has the same tripeptide core as the copper peptide it is compared against.
Not medical advice
This page reports what has been documented about a compound. It is not medical advice, not a diagnosis, not a dosing protocol, and not a recommendation to obtain or use anything described here. Talk to a licensed clinician about anything concerning your health. Read the full disclaimer.
Reviewed against editorial standards Updated
The short answer
Matrixyl on its own is palmitoyl pentapeptide-4, a collagen fragment with a fatty tail. Matrixyl 3000 adds palmitoyl tripeptide-1 and tetrapeptide-7. Palmitoyl tripeptide-1 is pal-GHK: glycyl-histidyl-lysine with a palmitic acid tail, the same tripeptide core as copper tripeptide-1, without the copper. Analytical chemistry work on anti-wrinkle creams uses both palmitoylated peptides in a single method, pal-GHK as the internal standard for measuring pal-KTTKS [2].
On evidence the two are less alike. The record for palmitoyl pentapeptide-4 rests on one double-blind, split-face, randomised trial in 93 women over 12 weeks, every author's stated affiliation a consumer products manufacturer's research laboratory [1]. Copper tripeptide-1 has two independent randomised trials, the larger in 86 evaluable patients with venous stasis ulcers in 1992 [11] and a smaller one with blinded evaluators in 13 patients in 2006 [3], and neither separated from its control on an objective measure. It is graded B on its own review because that randomised evidence exists and has read out, which is the only thing the letter records. No independent trial of the palmitoyl tripeptide-1 and tetrapeptide-7 combination could be found.
Side by side
| Property | GHK-Cu (copper tripeptide-1) | Matrixyl (palmitoyl pentapeptide-4) |
|---|---|---|
| The shared core | Its tripeptide core is glycyl-histidyl-lysine | Palmitoyl tripeptide-1 inside the Matrixyl 3000 blend is pal-GHK: the same core, palmitoylated, without the copper. Both palmitoylated peptides appear together in one analytical method for anti-wrinkle creams [2] |
| Best independent human trial | Two of them, both negative on their objective measures. The larger, in 1992, randomised 86 evaluable patients with venous stasis ulcers to a copper tripeptide cream, silver sulfadiazine or an inert vehicle: the copper arm did not differ from the vehicle while silver sulfadiazine beat both [11]. The smaller, after laser resurfacing with 13 patients completing and blinded evaluators, found no significant difference in redness, wrinkles or skin quality, with only a validated patient questionnaire separating at p equals 0.04 [3] | None found. The trial the ingredient is known for came from a manufacturer's research laboratory: 93 women over 12 weeks, split-face and double-blind, the peptide side showing significant reduction in wrinkles and fine lines [1] |
| Evidence for the blend that is actually sold | Not applicable | None found. The nearest work is split-face studies of finished products carrying the peptides alongside other actives, again authored from a manufacturer [6] |
| Legal position in the United States | A listed cosmetic ingredient, lawfully sold and advertised on appearance, with registration, listing, safety substantiation and adverse event duties and labelling at 21 CFR part 701 [8] [9] [10] | The same, and nothing in it requires evidence of effect from either |
| Evidence grade on this site | Grade B. The scale measures how much research exists and how good it is, never which way it came out, so the direction is carried in words beside the letter on the review itself | Not graded here. The source review a grade is derived from has not been run on palmitoyl pentapeptide-4 |
Why the two get mixed up
Start with the names. Matrixyl, Matrixyl 3000 and copper peptide are the names on the front of the box; underneath them sit palmitoyl pentapeptide-4, a three-component blend, and copper tripeptide-1. A trade name in this category carries no information about the chemistry beneath it, and nothing in the branding tells a reader that one of those three has a component built on the same tripeptide as the other product on the shelf.
That component is palmitoyl tripeptide-1: glycyl-histidyl-lysine with a palmitic acid tail, which is why the analytical chemistry literature treats it as the companion to pal-KTTKS, using it as the internal standard in a 2009 method for assaying palmitoyl peptides in anti-wrinkle creams [2]. Same core, different modification: one pairs it with a copper ion, the other with a lipid tail chosen to help it cross skin.
A second source of confusion is that one trade name covers two products, the pentapeptide on its own and the three-peptide blend. The 2005 trial the ingredient is famous for tested the single pentapeptide, not the blend [1], while most of what is sold under the name is the blend. Both also sit inside cosmetic law, which sets no evidence bar: a product may lawfully carry either ingredient and claim an appearance effect, with no agency reviewing it before sale [8] [9]. So the difference a shopper can check is who ran each study and what each one measured.
What the published record covers for each
The palmitoyl pentapeptide-4 record is one trial, better designed than most in this category. Ninety-three white women aged 35 to 55 took part in a 12 week, double-blind, split-face, randomised study comparing a moisturiser against the same moisturiser carrying the pentapeptide at 3 parts per million. The peptide side showed significant reduction in wrinkles and fine lines against the control side, by instrumental image analysis, by expert grader assessment and in self-assessment [Human RCT] [1]. Every author lists a consumer products manufacturer research laboratory as their affiliation, which does not make the result wrong and does leave it a single source without independent replication.
The GHK-Cu record runs the other way and is independent. Patients randomised after carbon dioxide laser resurfacing of the skin around the mouth, 13 completing, were assessed by computer analysis and by blinded evaluators, and neither found a statistically significant difference in redness, wrinkles or overall skin quality. The single measure that separated was a validated patient questionnaire, at p equals 0.04 [Human RCT] [3]. Thirteen patients is a small trial, and a small trial that finds nothing has not established that there is nothing to find.
Set the two side by side and the pattern is the informative part. The larger trial was run by an interested party and reported a difference. The smaller was independent, blinded its evaluators, and reported a difference only on the endpoint subjects filled in themselves. Neither is a verdict about either molecule, and both are facts about how this category produces evidence.
Underneath both is the same physical problem. In excised human skin the palmitoylated pentapeptide was more stable in skin homogenate than the bare one, and both showed limited passive permeation, with a separate study reporting a 2 to 22 fold signal improvement once microneedles breached the barrier [In-vitro] [5] [7]. For the copper peptide, almost no peptide and almost no copper crossed intact human skin in a two-model laboratory study [In-vitro] [4]. Those are measurements in excised tissue and diffusion systems, not on a living face, and what they establish is how much of the difficulty is physical.
The blend that outsells the single ingredient has no trial of its own. A search for an independent randomised trial of the palmitoyl tripeptide-1 and tetrapeptide-7 combination returned nothing. The nearest published work is a pair of split-face studies of finished anti-ageing products carrying the peptides alongside niacinamide, carnosine and retinyl propionate, in 42 and 35 subjects, again authored from a manufacturer [Human RCT] [6]. Those studies tested products rather than ingredients, and no arm isolated a peptide.
Our takeOne of the peptides inside the Matrixyl 3000 blend is built on the same tripeptide as the copper peptide it is sold against. That shared core appears in the marketing on neither side, and the evidence gap between the two is smaller than the branding gap.
Frequently asked questions
Do GHK-Cu and Matrixyl share a chemical core?
Not the two headline ingredients, but one component of the Matrixyl 3000 blend does. Palmitoyl tripeptide-1 is pal-GHK: the same tripeptide core as copper tripeptide-1, with a palmitic acid tail and without the copper. Analytical chemistry work on anti-wrinkle creams uses pal-GHK and pal-KTTKS together in one method [2].
What is the difference between Matrixyl and Matrixyl 3000?
Matrixyl is palmitoyl pentapeptide-4 on its own. Matrixyl 3000 adds palmitoyl tripeptide-1 and tetrapeptide-7. The 2005 split-face trial the ingredient is known for tested the single pentapeptide at 3 parts per million [1], and no independent randomised trial of the blend could be found.
Which of the two has better evidence?
Not a question this page answers, and the records are not the same shape. Palmitoyl pentapeptide-4 has one 12 week double-blind split-face trial in 93 women, authored from a manufacturer's research laboratory [1]. Copper tripeptide-1 has two independent randomised trials, at 86 evaluable patients in 1992 and 13 in 2006, and neither separated from its control on an objective measure [3] [11]. It carries a grade on this site, B, derived from those tiers; palmitoyl pentapeptide-4 has not had this site's identifier-level source review run on it and carries no grade.
Does anyone check either ingredient before it goes on sale?
No. The Modernization of Cosmetics Regulation Act of 2022 added registration, listing, safety substantiation and adverse event duties [8] [9], with labelling under 21 CFR part 701 [10]. It created no pre-market approval step for an ingredient and no requirement to substantiate an efficacy claim to a regulator.
Has anyone tested the two against each other?
No published head to head between copper tripeptide-1 and either the pentapeptide on its own or the three-peptide blend could be found. Every comparative statement in circulation rests on supplier material, or on reading one trial against another that used a different design, population and endpoint set.
References
- Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005. PMID 18492182 DOI 10.1111/j.1467-2494.2005.00261.x
- Chirita RI, Chaimbault P, Archambault JC, Robert I, Elfakir C. Development of a LC-MS/MS method to monitor palmitoyl peptides content in anti-wrinkle cosmetics. Anal Chim Acta. 2009. PMID 19393372 DOI 10.1016/j.aca.2009.03.015
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. PMID 16847171 DOI 10.1001/archfaci.8.4.252
- Li H, Low YS, Chong HP, Zin MT, Lee CY, Li B, Leolukman M, Kang L. Microneedle-Mediated Delivery of Copper Peptide Through Skin. Pharm Res. 2015. PMID 25690343 DOI 10.1007/s11095-015-1652-z
- Choi YL, Park EJ, Kim E, Na DH, Shin YH. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS). Biomol Ther (Seoul). 2014. PMID 25143811 DOI 10.4062/biomolther.2014.053
- Kaczvinsky JR, Griffiths CE, Schnicker MS, Li J. Efficacy of anti-aging products for periorbital wrinkles as measured by 3-D imaging. J Cosmet Dermatol. 2009. PMID 19735523 DOI 10.1111/j.1473-2165.2009.00444.x
- Mohammed YH, Yamada M, Lin LL, Grice JE, Roberts MS, Raphael AP, Benson HA, Prow TW. Microneedle enhanced delivery of cosmeceutically relevant peptides in human skin. PLoS One. 2014. PMID 25033398 DOI 10.1371/journal.pone.0101956
- United States Congress. Consolidated Appropriations Act, 2023, Public Law 117-328, enacted 29 December 2022. Division FF, title III, subtitle E is the Modernization of Cosmetics Regulation Act of 2022, which adds subchapter VI of the Federal Food, Drug, and Cosmetic Act. govinfo. 2022. Source document
- Office of the Law Revision Counsel, United States House of Representatives. Federal Food, Drug, and Cosmetic Act, title 21 of the United States Code: section 321 for the definitions of drug and cosmetic, and subchapter VI sections 364 to 364d for cosmetic definitions, adverse events, registration and product listing, and safety substantiation. Checked 2 August 2026. United States Code. 2026. Source document
- Office of the Federal Register and Government Publishing Office. Cosmetic labeling, title 21 of the Code of Federal Regulations, part 701. Checked 2 August 2026. Electronic Code of Federal Regulations. 2026. Source document
- Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, Heggers JP, Hill DP Jr, Taylor EL, Robson MC. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992. PMID 1495150 DOI 10.1067/mva.1992.37086